GLP‑1s preserve muscle, study says

These drugs work by making people feel full sooner and keeping food in the stomach longer, so total calorie intake falls without the white-knuckle hunger of older diets. Semaglutide is the medicine in Wegovy, and tirzepatide is the medicine in Zepbound, which also activates a second gut-hormone pathway called glucose-dependent insulinotropic polypeptide. (nejm.org) (accessdata.fda.gov) The catch is that weight loss is never just fat loss. When body weight drops fast, the body usually gives up some lean mass too, and lean mass includes muscle along with water, organs, and other non-fat tissue. (ajcn.nutrition.org) (pmc.ncbi.nlm.nih.gov) That is why this new report got attention. A study being presented at the European Congress on Obesity in Málaga on May 11-14, 2025 said people using glucagon-like peptide-1 drugs or dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide drugs lost body fat over 6 months with only minimal lean-mass loss. (news-medical.net) The important detail is that this is a meeting abstract, not a full peer-reviewed paper. Conference previews are useful for spotting trends, but they usually give less detail on who was enrolled, how body composition was measured, and how well the result held up across different ages and training levels. (news-medical.net) That caution matters because the broader literature has been much less reassuring. A 2026 systematic review and meta-analysis covering 20 randomized trials and 15,782 participants found lean mass made up 25% to 39% of total weight lost on incretin drugs, including 35.2% with semaglutide and 25.4% with tirzepatide. (waltersport.com) That same review found lifestyle-only programs were not dramatically better, with 26.2% of lost weight coming from lean mass. The best result came from lifestyle programs that added resistance training, where the lean-mass share fell to 17.5%. (waltersport.com) So the real story is not “these drugs melt muscle” or “these drugs spare muscle.” The real story is that body composition seems to depend on the setup around the drug, especially protein intake, strength training, and whether doctors are tracking more than the scale. (waltersport.com) (clinicaltrials.gov) Researchers are now building trials around exactly that question. One registered 2026 study, called Lean Mass Preservation With Resistance Exercise and Protein During Semaglutide and Tirzepatide Therapy, plans four groups over 6 months: control, higher protein, muscle-strengthening exercise, and both together. (clinicaltrials.gov) For athletes and regular lifters, the practical implication is narrower than the hype. “Lean mass” is not the same thing as “strength,” and a scan showing preserved lean tissue does not automatically prove someone kept the same squat, sprint speed, or training capacity. (ajcn.nutrition.org) (pmc.ncbi.nlm.nih.gov) What would really change the conversation is a full paper showing preserved body fat loss, preserved measured muscle, and preserved performance in trained people over time. This abstract is an intriguing signal, but the heavier evidence still says the barbell, the protein target, and the body-composition scan matter as much as the prescription. (news-medical.net) (waltersport.com)